

Enhanced Annual Drug List Updates

April 2020

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
DIVIGEL (estradiol td gel 1.25 mg/1.25gm (0.1%))	Brand	Addition, Preferred Status
GVOKE PFS (glucagon subcutaneous soln pref syringe 0.5 mg/0.1ml)	Brand	Addition, Preferred Status
GVOKE PFS (glucagon subcutaneous soln pref syringe 1 mg/0.2ml)	Brand	Addition, Preferred Status
HARVONI (ledipasvir-sofosbuvir tab 45-200 mg)	Brand	Addition, Preferred Status
INSULIN ASPART (insulin aspart inj 100 unit/ml)	Brand	Addition, Preferred Status
INSULIN ASPART FLEXPEN (insulin aspart soln pen-injector 100 unit/ml)	Brand	Addition, Preferred Status
INSULIN ASPART PENFILL (insulin aspart soln cartridge 100 unit/ml)	Brand	Addition, Preferred Status
INSULIN ASPART PROTAMINE/INSULIN ASPART (insulin aspart prot & aspart (human) inj 100 unit/ml (70-30))	Brand	Addition, Preferred Status
INSULIN ASPART PROTAMINE/INSULIN ASPART FLEXPEN (insulin aspart prot & aspart sus pen-inj 100 unit/ml (70-30))	Brand	Addition, Preferred Status
LYNPARZA (olaparib cap 50 mg)	Brand	Addition, Preferred Status
LYNPARZA (olaparib tab 100 mg)	Brand	Addition, Preferred Status
LYNPARZA (olaparib tab 150 mg)	Brand	Addition, Preferred Status
NOVOLIN N FLEXPEN (insulin nph (human) (isophane) susp pen-injector 100 unit/ml)	Brand	Addition, Preferred Status
NOVOLIN R FLEXPEN (insulin regular (human) soln pen-injector 100 unit/ml)	Brand	Addition, Preferred Status
NUBEQA (darolutamide tab 300 mg)	Brand	Addition, Preferred Status
ROZLYTREK (entrectinib cap 100 mg)	Brand	Addition, Preferred Status
ROZLYTREK (entrectinib cap 200 mg)	Brand	Addition, Preferred Status
RUBRACA (rucaparib camsylate tab 200 mg (base equivalent))	Brand	Addition, Preferred Status
RUBRACA (rucaparib camsylate tab 250 mg (base equivalent))	Brand	Addition, Preferred Status
RUBRACA (rucaparib camsylate tab 300 mg (base equivalent))	Brand	Addition, Preferred Status
RYBELSUS (semaglutide tab 14 mg)	Brand	Addition, Preferred Status
RYBELSUS (semaglutide tab 3 mg)	Brand	Addition, Preferred Status
RYBELSUS (semaglutide tab 7 mg)	Brand	Addition, Preferred Status
SOVALDI (sofosbuvir tab 200 mg)	Brand	Addition, Preferred Status
TEMIXYS (lamivudine-tenofovir disoproxil fumarate tab 300-300 mg)	Brand	Addition, Preferred Status
TRIFLURIDINE (trifluridine ophth soln 1%)	Brand	Addition, Preferred Status
TRIKAFTA (elexacaf-tezacaf-ivacaf 100-50-75 mg & ivacaftor 150 mg tbpk)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.